

Application No. 10/800,077
Reply to Office Action of February 12, 2009

Docket No.: VASG **RECEIVED**
CENTRAL FAX CENTER

AMENDMENTS TO THE CLAIMS

APR 08 2009

The Claim Listing below will replace all prior versions of the claims in the application:

Listing of Claims:

1. (Currently amended) An isolated nucleic acid compound between 20 and 35 nucleotides in length, which is 100% complementary to a region of an EphB4 transcript sequence set forth in SEQ ID NO: 392, wherein the nucleic acid compound decreases expression of EphB4 in a cell, and wherein the nucleic acid compound is an antisense nucleic acid compound comprising the sequence of SEQ ID NO: 231 and one or more modified backbone or base moieties.
- 2-6. (Canceled)
7. (Original) The nucleic acid compound of claim 1, wherein the nucleic acid compound is single-stranded.
8. (Original) The nucleic acid compound of claim 1, wherein the nucleic acid compound is double-stranded.
9. (Previously presented) The nucleic acid compound of claim 1, wherein the nucleic acid compound is a DNA molecule.
10. (Previously presented) The nucleic acid compound of claim 1, wherein the nucleic acid compound is a RNA molecule.
11. (Previously presented) The nucleic acid compound of claim 1, wherein the nucleic acid compound comprises a DNA strand and a RNA strand.
- 12-15. (Canceled)
16. (Previously presented) The nucleic acid compound of claim 1, wherein the antisense nucleic acid compound has at least one internucleotide linkage selected from the group consisting of alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxylmethyl esters, carbonates, and phosphate triesters.

Application No. 10/800,077
Reply to Office Action of February 12, 2009

Docket No.: VASG-P01-001

17-58. (Canceled)

59. (Currently amended) A pharmaceutical composition comprising a nucleic acid compound and a pharmaceutically acceptable carrier, wherein the nucleic acid compound is between 20 and 35 nucleotides in length and is 100% complementary to a region of an EphB4 transcript sequence set forth in SEQ ID NO: 392, wherein the nucleic acid compound decreases expression of EphB4 in a cell, and wherein the nucleic acid compound is an antisense nucleic acid compound comprising the sequence of SEQ ID NO: 231 and one or more modified backbone or base moieties.

60-91. (Canceled)

92. (Previously presented) The nucleic acid compound of claim 1, wherein the antisense nucleic acid comprises at least one 2'-O-alkylated ribonucleotide.

93. (Previously presented) The pharmaceutical composition of claim 59, wherein the antisense nucleic acid comprises at least one 2'-O-alkylated ribonucleotide.